Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC (FOLFOX) plus camrelizumab and apatinib for potentially resectable primary hepatocellular carcinoma
ChiCTR2200062214Phase 4Not yet recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Jul 2022
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab, Rivoceranib, oxaliplatin, fluorouracil and folinic acid in hepatocellular carcinoma (HCC), sponsored by First Hospital of China Medical University. Primary endpoint: Conversion success rate. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
camrelizumabRivoceraniboxaliplatinfluorouracilfolinic acid
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2200062214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062214.